Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,786 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Colorectal Clear all
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

Glutamine PET Imaging Colorectal Cancer

NCT03275974
View directory record Official record
Conditions
RAS Wild Type, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography, Blood Draw
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Phase 3 Interventional

Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease

NCT00002570
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 79 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2009
U.S. locations
16
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People

NCT04336397
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Multi-target stool DNA test, Colonoscopy
Diagnostic Test
Lead sponsor
Alaska Native Tribal Health Consortium
Other
Eligibility
45 Years to 75 Years
Enrollment
2,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethel, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 13, 2026, 5:09 PM EDT
Active, not recruiting No phase listed Observational

Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases

NCT07861360
View directory record Official record
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
Initiation of trifluridine-tipiracil plus bevacizumab, Initiation of trifluridine-tipiracil alone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Not applicable Interventional

Increasing Colorectal Cancer Screening Among Filipino Americans

NCT00742729
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Arm 1, Arm 2, Arm 3
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 70 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 13, 2026, 5:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502
View directory record Official record
Conditions
Liver Resection, Colorectal Carcinoma Liver Metastases
Interventions
HRX215 capsules, Placebo capsules
Drug
Lead sponsor
HepaRegeniX GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Increasing Colorectal Cancer Screening in African Americans

NCT00893295
View directory record Official record
Conditions
Colorectal Cancer
Interventions
informational intervention, medical chart review, screening questionnaire administration, study of socioeconomic and demographic variables, barium enema injection, colon imaging study, screening colonoscopy, sigmoidoscopy
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
50 Years to 79 Years
Enrollment
896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 13, 2026, 5:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Deep South Surgical Equity Research Network: Addressing Socioecological Determinants of Health

NCT05345054
View directory record Official record
Conditions
Colorectal Cancer, Inflammatory Bowel Diseases, Diverticular Diseases, Social Behavior
Interventions
no intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Alexander City, Alabama • Demopolis, Alabama • Greenville, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 13, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

NCT06599502
View directory record Official record
Conditions
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions
AZD0022, Cetuximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Duarte, California • New York, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Not applicable Interventional Results available

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

NCT00574353
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Not applicable Interventional Results available

Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care

NCT01468675
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Coronary Heart Disease, Diabetes
Interventions
Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
6,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02873195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo
Drug · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 13, 2026, 5:09 PM EDT
Terminated Not applicable Interventional Results available

SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

NCT05010850
View directory record Official record
Conditions
Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
Interventions
Colovac, Stoma Creation
Device · Procedure
Lead sponsor
SafeHeal Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 13, 2026, 5:09 PM EDT
Completed No phase listed Observational

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

NCT00442520
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 13, 2026, 5:09 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Community-Based Educational Intervention to Improve Colorectal Cancer Screening

NCT04392050
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Interview, Focus Group, Questionnaire Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 13, 2026, 5:09 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Choose It and Use It: Choice, Implementation Intentions and At-Home Colorectal Cancer Screening

NCT06085560
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Usual Care Message, Implementation Intention Intervention: Standard Message, Implementation Intention Intervention: Culturally-Targeted Message
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
45 Years to 72 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Results available

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

NCT02365480
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Berberine Chloride, Laboratory Biomarker Analysis, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 13, 2026, 5:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Interventions
IMT-009, Fruquintinib
Drug · Combination Product
Lead sponsor
Immunitas Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 13, 2026, 5:09 PM EDT
Recruiting Early Phase 1 Interventional

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

NCT07627191
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
Interventions
GLP1-RA (semaglutide)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 5:09 PM EDT
Not listed No phase listed Observational

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Andrew Kennedy
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 13, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 13, 2026, 5:09 PM EDT